氟伐他汀对首次成功的PCI术后心血管事件的预防作用

目的探讨氟伐他汀对冠心病首次成功的经皮冠状动脉介入治疗（PCI）术后主要不良心血管事件（MACE）的影响。方法86例首次成功PCI术后患者。总胆固醇水平在3．5-7．0mmol／L（135-270mg／dL）之间。空腹甘油三脂水平小于4．5mmol／L（400mg／dL）。随机分为治疗组（常规治疗外，加服氟伐他汀，44例）和对照组（仅常规治疗。42例）。治疗组氟伐他汀40mg／d。比较治疗组和对照组间无主要不良心血管事件（MACE）的生存时间。结果治疗组无主要不良心血管事件（MACE）的生存时间显著延长（P=0．01），治疗组有9例（20．5％），对照组有11例（26．2％）患者至少发生了一次主要不良心血管事件（MACE）P=0．01。结论对总胆固醇水平正常或轻度升高，首次成功的经皮冠状动脉介入治疗（PCI）的冠心病患者，氟伐他汀可显著减少主要不良心血管事件发生（MACE）的危险性。

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention

Objective] To determine whether treatment with fluvastatin reduces MACE in patients who have undergone PCI. Methods] 86 patients with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dL (3.5~7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L) were randomly assigned to receive treatment with fluvastatin, treatment group 40 mg/d, or control group at hospital discharge for 3 to 4 years. Results] MACE-free survival time was significantly longer in the fluvastatin group than in the control group (P =0.01). Nine (20.5%) of 44 patients in the fluvastatin group and Eleven (26.2%) of 42 patients in the placebo group had at least 1 MACE. Conclusion] Fluvastatin treatment in patients with average cholesterol levels undergoing their first successful PCI significantly reduces the risk of major adverse cardiac events.